

Ref. No: 0318
Date: 06/10/23
Subject: Lung Cancer Treatments

REQUEST

1. How many Non-small cell lung cancer (NSCLC) patients were treated in the past 3 months with:
 - ALK Inhibitors (Alectinib, Brigatinib, Ceritinib, Crizotinib, Lorlatinib)
 - Amivantamab
 - Atezolizumab Monotherapy
 - Atezolizumab + Bevacizumab + Carboplatin + Paclitaxel
 - Dabrafenib + Trametinib
 - Docetaxel monotherapy or in combination with Carboplatin / Cisplatin
 - Durvalumab
 - Gemcitabine
 - Nitedanib + Docetaxel
 - Nivolumab
 - Osimertinib
 - Other EGFR Inhibitors (Afatinib, Erlotinib, Gefitinib, Dacomitinib, Mobocertinib)
 - Paclitaxel
 - Pembrolizumab Monotherapy
 - Pembrolizumab + Paclitaxel + Platinum (Carboplatin / Cisplatin)
 - Pembrolizumab + Pemetrexed + Platinum (Carboplatin / Cisplatin)
 - Pemetrexed + Platinum (Carboplatin / Cisplatin)
 - RET Inhibitors (Pralsetinib, Selpercatinib)
 - Sotorasib
 - Tepotinib
 - Vinorelbine monotherapy or in combination with Carboplatin / Cisplatin
 - Other active systemic anti-cancer therapy
 - Palliative care only
2. Does your Trust / Health Board participate in any clinical trials for non-small cell lung cancer (NSCLC)? If so, could you please provide the name of each active trial and the number of patients taking part.

RESPONSE

1. **How many Non-small cell lung cancer (NSCLC) patients were treated in the past 3 months with:**

Nil

2. **Does your Trust / Health Board participate in any clinical trials for non-small cell lung cancer (NSCLC)? If so, could you please provide the name of each active trial and the number of patients taking part.**

We do not currently have any clinical trials for non-small cell lung cancer (NSCLC).